Five-Gene Biomarker Signature for Active Tuberculosis Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current tuberculosis diagnostics face challenges with delayed results and inadequate sensitivity, particularly in extrapulmonary TB and immunocompromised patients, due to the need for accessible samples and the limitations of microbiological tests.
Innovation Solution
A novel five-gene biomarker signature, including BATF2, CD177, haptoglobin, immunoglobulin J chain, and galectin 10, is identified for diagnosing active tuberculosis, allowing for rapid and sensitive detection across various patient cohorts, including those with extrapulmonary TB and HIV infection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If microbiological identification methods are used for TB diagnosis, then diagnostic accuracy is improved, but sampling difficulty and time delay increase
Solution Approach 1:
The patent extracts the diagnostic target from the traditional microbiological approach by identifying and measuring specific host gene expression signatures (BATF2, CD177, HP, IGJ, CLC) in blood samples. This extraction allows diagnosis without requiring direct detection of Mtb bacteria or tissue samples from the disease site, thereby reducing sampling difficulty and time delay while maintaining diagnostic accuracy.
Solution Approach 2:
The patent introduces host gene expression signatures as intermediary biomarkers that mediate between the TB infection and the diagnostic test. Instead of directly detecting the pathogen or requiring invasive sampling, the test measures these intermediary molecular signatures in easily obtainable blood samples, resolving the contradiction between diagnostic accuracy and sampling difficulty.
2Measurement precision
If liquid culture systems are used for TB detection, then sensitivity is improved, but detection time increases to 10-19 days
Solution Approach 1:
The patent applies preliminary action by pre-identifying and validating a panel of five genes (BATF2, CD177, HP, IGJ, CLC) that are differentially expressed in TB patients before clinical use. This preliminary characterization allows the test to provide rapid results (within hours) while maintaining the sensitivity of traditional culture systems, as the gene signatures are already optimized for TB detection.
Solution Approach 2:
The patent substitutes the mechanical/cultural detection system with a molecular detection system. Instead of relying on slow bacterial growth in liquid culture, the test uses PCR-based detection of host gene expression signatures, which can be performed rapidly on blood samples. This substitution maintains sensitivity while dramatically reducing detection time from 10-19 days to hours.
3Measurement precision
If a large number of genes are included in the diagnostic signature, then diagnostic accuracy is improved, but test complexity increases
Solution Approach 1:
The patent extracts and selects only the five most informative genes (BATF2, CD177, HP, IGJ, CLC) from the broader transcriptome that are most discriminating for TB diagnosis. By taking out only the essential genes rather than analyzing all expressed genes, the test achieves high diagnostic accuracy while minimizing complexity. This extraction principle reduces the test from potentially hundreds of genes to just five key markers.
Solution Approach 2:
The patent applies parameter changes by optimizing the number and selection of genes in the diagnostic signature. Through statistical analysis and validation, the researchers determined that five genes provide the optimal balance between diagnostic accuracy and test complexity. This parameter optimization ensures that the test is both accurate and manageable for clinical implementation.
Data Source
AI summary
The present invention relates to a method of determining the presence or absence of active tuberculosis in a sample, in particular, comprising determining the levels of one or more biomarkers selected from basic leucine zipper transcription factor ATF-like 2 (BATF2), cluster of differentiation 177 (CD177), haptoglobin (HP), immunoglobulin J chain (IGJ) and galectin 10 (CLC), in said sample. Uses of biomarkers of the invention and kits for performing the method of the invention are also described.